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Abstract
Background: Recent data indicate that chronic use of coxibs leads to an increased occurrence of
thrombotic cardiovascular events. This raises the question as to whether traditional non-steroidal
anti-inflammatory drugs (tNSAIDs) might also produce similar hazards. Our aim has been to
evaluate the association between the chronic use of tNSAIDs and the risk of myocardial infarction
(MI) in patients.
Methods: We performed a nested case-control analysis with 4,975 cases of acute MI and 20,000
controls, frequency matched to cases by age, sex, and calendar year.
Results:  Overall, current use of tNSAID was not associated with an increased risk of MI
(RR:1.07;95%CI: 0.95–1.21). However, we found that the relative risk (RR) of MI for durations of
tNSAID treatment of >1 year was 1.21 (95% CI, 1.00–1.48). The corresponding RR was 1.34 (95%
CI, 1.06–1.70) for non-fatal MI. The effect was independent from dose. The small risk associated
with long-term use of tNSAIDs was observed among patients not taking low-dose aspirin (RR: 1.29;
95% CI, 1.01–1.65). The effect of long-term use for individual tNSAIDs ranged from a RR of 0.87
(95% CI, 0.47–1.62) with naproxen to 1.38 (95% CI, 1.00–1.90) with diclofenac.
Conclusion:  This study adds support to the hypothesis that chronic treatment with some
tNSAIDs is associated with a small increased risk of non-fatal MI. Our data are consistent with a
substantial variability in cardiovascular risks between individual tNSAIDs.
Background
The recent withdrawal of rofecoxib together with new data
showing that other cyclo-oxygenase-2 (COX-2) inhibitors
might also be associated with an increased risk of develop-
ing adverse cardiovascular events, mainly acute myocar-
dial infarction (MI), has created a climate of uncertainty
surrounding the safety of these drugs and traditional non-
steroidal anti-inflammatory drugs (tNSAIDs) [1,2]. In
particular, this latter concern has been fostered by the pre-
liminary communication of a press release suggesting that
naproxen may be associated with an increased risk of car-
diovascular and cerebrovascular events [3]. Two recently
published studies found a similar result [4,5]. A feature in
these newly released reports was that an increased risk
only became apparent after prolonged administration of
the suspected agent (in particular, coxibs), and notably in
patients at a relatively low initial risk of cardiovascular
disease.
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Recently, we published a large epidemiologic study that
evaluated the association between tNSAIDs as a class, as
well as individual tNSAIDs, and the risk of MI [6]. Our
overall estimate for tNSAIDs was compatible with either
no association or a small increased risk, while the corre-
sponding estimate for naproxen was compatible with
either no association or a small reduced risk. We reported
only briefly on the effect of duration of therapy in that
paper, but now present more detailed information on the
impact of duration of treatment on the relationship
between tNSAIDs and MI.
Methods
We have used the same data set and similar analytical
models to those previously reported [6]. In brief, the
design was of a prospective cohort study with nested case-
control analysis. Overall 4,975 cases of acute MI and
death from coronary heart disease (CHD) aged 50 to 84
years were identified between 1997 and 2000, using the
UK General Practice Research Database. A total of 20,000
controls were randomly sampled and frequency matched
to cases by age, sex, and calendar year. Both cases and con-
trols were required to be enrolled with their general prac-
titioner for at least two years before entering the study.
Using this data set, we estimated the effect of duration of
tNSAIDS as a class and 3 individual tNSAIDs (diclofenac,
ibuprofen and naproxen) on the risk of MI. We computed
estimates of odds ratios using unconditional logistic
regression to estimate the relative risks (RR)[7], and 95%
confidence interval (CI) of MI associated with current use
of tNSAIDs compared to non-use. Estimates were adjusted
for sex, age, calendar year, anemia, smoking status, alco-
hol use, diabetes, hypertension, hyperlipidemia, body
mass index, rheumathoid arthritis, osteoarthritis, prior
cardiovascular disease, use of steroids, anticoagulants,
aspirin, and paracetamol. We performed several sensitiv-
ity analyses to see whether the observed effect was inde-
pendent of variations in the operational definition of
exposure as well as duration. In the main analysis, we
identified NSAID prescriptions before the index date for
cases and controls, and categorized exposure to NSAIDs as
in the original publication: "current," when the supply of
the most recent prescription lasted until index date or
ended in the 30 days before the index date; "recent," when
it ended between 31 and 180 days before the index date;
"past," when it ended between 6 months and 2 years
before the index date; and "non-use," when there was no
recorded use in the 2 years before the index date. We
repeated the same regression models using a more restric-
tive time-window for current use of 7 days prior to the
index date. We studied the effect of duration among cur-
rent users, and evaluated duration of use adding the peri-
ods of "consecutive" prescriptions, defined as an interval
of <1 month (main analysis) between the end of supply of
one prescription (assuming adherence) and the date of
prescription of the subsequent one. In secondary analyses
of duration, we varied the interval to be either <1 week or
<2 months. Finally, we performed 2 additional analyses:
first one on "new current users" (those current users who
did not receive a prescription for an NSAID in the 6
months prior to starting on NSAIDs); and the second
being past users of NSAIDs (patients with NSAID use that
ended between 31 days and 2 years before the index date)
as the reference group.
Results
Overall, current intake of tNSAIDs was associated with a
RR of 1.07 (95% CI, 0.95–1.21; Figure 1). The corre-
sponding estimate when defining current exposure as use
within a week prior to index date was 1.02 (95% CI, 0.90–
1.17). The risk for treatment duration <1 year was no dif-
ferent from non-use, and for treatment duration >1 year,
the RR was 1.21 (95% CI, 1.00–1.48): test for duration
response trend, p .04. This estimate was slightly increased
when using past users of NSAID as the reference group
(RR:1.34;95%CI: 1.10–1.64). The median duration of use
among long-term users was 2.8 years among cases and 2.6
among controls. A similar pattern of small increased risk
of MI with longer duration was present with diclofenac,
while this trend was not apparent for ibuprofen. On the
other hand, the estimate of current use of naproxen was
compatible with either no association or a small reduced
risk of MI. The effect was present after a treatment of 1
month and persisted over longer durations of use (RR:
0.86; 95% CI, 0.58–1.27). Estimates of duration effects
for tNSAIDs overall and naproxen, in particular, with 3
different assumptions about intervals between tNSAID
use applied in the definition of the duration variables
(Table 1). The increased risk with long-term treatment of
tNSAIDs was most apparent when gaps between consecu-
tive prescriptions were not permitted to exceed 7 days (RR:
1.31; 95% CI, 0.94–1.81). The varying intervals had no
major impact on the estimates of duration-response asso-
ciated with naproxen. We performed a similar sensitivity
analysis for exposure to inhaled steroids (a priori not asso-
ciated with MI). The estimates were similar in the 3 differ-
ent scenarios (in order of increasing laxitude in the gap
definition: 0.97 (0.62–1.49);0.95 (0.72–1.26);1.12
(0.91–1.37)). The duration effect of NSAIDs according to
the concomitant use of low-dose aspirin and daily dose of
tNSAIDs is shown in Table 2. The excess risk associated
with long term use of tNSAIDs was observed among
patients not taking concomitantly low-dose aspirin (RR:
1.29; 95% CI, 1.01–1.65), while long term use of tNSAIDs
did not appear to increase the risk of MI among patients
taking cardioprotective aspirin (RR: 0.90; 95% CI, 0.61–
1.32). Data were too scarce to evaluate the interaction
between aspirin use and chronic treatment with individ-
ual NSAIDs. No major variation in the risk of MI associ-
ated with chronic use of tNSAIDs was observed betweenBMC Medicine 2005, 3:17 http://www.biomedcentral.com/1741-7015/3/17
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users of low-medium dose versus high dose (Table 2). The
corresponding estimates of RR associated with NSAID
duration of >1 year for fatal and non-fatal MI were 1.02
(95% CI, 0.76–1.37) and 1.34 (95% CI, 1.06–1.70),
respectively. The corresponding estimates of non-fatal MI
for diclofenac, ibuprofen, and naproxen were 1.82 (1.27–
2.62), 1.19 (0.70–2.03), and 1.00 (0.48–2.10), respec-
tively. "New current users" with duration of use longer
than 1 year had a RR of 1.31 (95%CI: 0.95–1.80).
Discussion
This additional analysis shows that use of tNSAIDs as a
class for duration of continuous use of <1 year in general
practice appears not to have a clinically relevant influence
on the occurrence of MI. Our data are also compatible
with the possibility that long-term therapy with tNSAIDs
may confer a small excess risk of developing MI of ~20%,
in particular of non-fatal MI. Our risk estimate is similar
to the one provided by the authors of the first published
epidemiologic study that analyzed the association
between tNSAIDs and MI, who reported an estimate of
relative risk for tNSAID duration longer than one year of
1.25; (95% CI, 0.90–1.72)[8]. The excess risk of MI
among chronic users appears to be independent of NSAID
daily dose and concentrated among patients not taking
low-dose cardioprotective aspirin (eg. patients on average
with a low cardiovascular profile). Our sensitivity analysis
on the impact of varying operational definitions of dura-
tion for tNSAIDs as a class yielded small differences in the
corresponding estimates associated with long-term treat-
ment. The most stringent criteria of requiring a gap or
interval of no greater than 1 week were the circumstances
Duration of use of NSAIDs and individual NSAIDs among current users (use within a month) and risk of MI Figure 1
Duration of use of NSAIDs and individual NSAIDs among current users (use within a month) and risk of MI. 
Overall, current use of tNSAIDs was associated with a RR of 1.07 (95% CI, 0.95–1.21). The corresponding estimates for 
diclofenac, ibuprofen and naproxen were 1.17 (0.98–1.40), 1.05 (0.86–1.28) and 0.89 (0.64–1.25), respectively. Duration of use 
was computed adding the periods of "consecutive" prescriptions, defined as an interval of less than one month between the 
end of supply of one prescription and the date of prescription of the subsequent one. Estimates are adjusted for sex, age, cal-
endar year, anemia, smoking status, alcohol use, diabetes, hypertension, hyperlipidemia, BMI, RA, OA, prior cardiovascular dis-
ease, use of steroids, anticoagulants, aspirin, paracetamol, and NSAIDs. The duration response trends for NSAIDs, diclofenac, 
ibuprofen and naproxen were P = .04, P = .02, P = .47, P = .54 respectively.
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under which the increased risk with long-term tNSAID
therapy was most noticeable, whereas the most liberal gap
(up to 2 months) revealed a relative risk closer to no
increased risk. This last result could be due in part to mis-
classification of the "true" continuous duration sequence
in real life.
Even though our study was not designed to make direct
comparissons between NSAIDs, we observed that at least
three individual NSAIDs (the 3 most widely used)
appeared to have different risk profile within a seemingly
heterogeneous group of tNSAIDS. A clear duration-
response was found for diclofenac, with an emerging risk
associated with chronic use extending over 1 year. Sec-
ondly, we found no clear trend with ibuprofen duration –
albeit that could, in part, be explained by some misclassi-
fication of exposure due to over the counter use of ibupro-
fen. Finally, there was no evidence of an increased risk
associated with naproxen use and our results are more
compatible with a minor reduced risk of MI. Misclassifica-
tion due to over the counter use could also be an issue for
naproxen. The risk with naproxen was relatively insensi-
tive to varying the interval used to calculate the length of
treatment duration. A potential small protective effect
associated with naproxen has been reported in most epi-
demiological studies [6], but not all [9]. These results are
at odds with the unpublished suggestion of a cardiovascu-
lar hazard from naproxen in a clinical trial stopped pre-
maturely last year and under controversial circumstances
[3]. The apparent level of protection afforded by regular
intake of naproxen in our study may be due to suppres-
sion of platelet thromboxane production, when adminis-
tered twice a day [11]. This is the mechanism by which
aspirin affords cardioprotection. However, unlike aspirin,
some, but not all patients, treated chronically with
naproxen maintain suppression of thromboxane through-
out the whole dosing interval at a level compatible with
effective platelet inhibition [10,11]. Furthermore, many
individuals classified as "chronic users" of naproxen in
this general population may not have been compliant
with the required dosing regimen (twice a day) all
throughout the period of prescribed drug intake further
diluting the benefit of an "aspirin effect". Thus, one would
not expect to observe a benefit similar to the one of low-
dose aspirin in the range of a 20–25% reduction in the
incidence of events. No other widely used tNSAID shares
the same pharmacodynamic/pharmacokinetic properties
of naproxen on platelets and consequently other tNSAIDs
are not expected to confer any degree of cardioprotection.
Due to scarce numbers of chronic users for other individ-
ual NSAIDs, we could not estimate their respective dura-
tion-response relationship. Yet, one can not assume a
class effect based on the heterogeneity observed between
the 3 individual NSAIDs. In particular, these observations
question the emerging strategy of comparing naproxen
with "non-naproxen tNSAIDs". Direct comparison of our
findings with those of recent coxib/tNSAID randomized
clinical trials (RCTs) are hampered by the use in RCTs of
significantly higher average daily doses of tNSAIDs
together with more strict compliance than the one occur-
ing in "real life" situations [1-3].
We analyzed the risk of inhaled steroids (a drug class con-
sidered a priori not to be associated one way or the other
with the risk of MI) to confirm the internal validity of our
sensitivity analysis of the operational definition of dura-
tion. The estimates of RR for long-term duration of
inhaled steroids changed minimally using the 3 different
intervals, ranging between 1.0 and 1.1. A limitation in the
interpretation of our results is the imprecision of most
Table 1: Duration of use of NSAIDs and naproxen among current users (use within a month) and risk of MI according to different 
definitions of the interval between consecutive prescriptions*
Interval = 7 days Interval = 30 days Interval = 60 days
OR (95%CI) † OR (95%CI) † OR (95%CI) †
NSAIDs
Dura 0–30 days 0.97 (0.83–1.14) 1.00 (0.82–1.21) 1.13 (0.92–1.40)
Dura 31–365 days 1.14 (0.97–1.34) 1.04 (0.89–1.23) 1.00 (0.83–1.19)
Dura >365 days 1.31 (0.94–1.81) 1.21 (1.00–1.48) 1.10 (0.93–1.30)
Naproxen‡
Dura 0–30 days 0.81 (0.49–1.35) 0.95 (0.52–1.75) 0.91 (0.46–1.79)
Dura > 30 days 0.94 (0.61–1.45) 0.86 (0.58–1.27) 0.88 (0.60–1.28)
* Duration of use was computed adding the periods of "consecutive" prescriptions, defined as varying intervals between the end of supply of one 
prescription and the date of prescription of the subsequent one.
† Estimates are adjusted for sex, age, calendar year, anemia, smoking status, alcohol use, diabetes, hypertension, hyperlipidemia, BMI, RA, OA, prior 
cardiovascular disease, use of steroids, anticoagulants, aspirin, paracetamol, and NSAIDs.
‡ Due to the limited number of observations in the duration strata of 31–365 days and the lack of heterogeneity in estimates of risk between this 
strata and the duration strata of greater than one year, we collapsed the two of them into one single duration strata.BMC Medicine 2005, 3:17 http://www.biomedcentral.com/1741-7015/3/17
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estimates of risk, given that the magnitude of the "true"
association we have purported to evaluate is most likely
weak, either of increased risk with long-term duration of
NSAIDs or reduced risk with naproxen. In this scenario,
the common limitations in all observational studies
(potential residual or unmeasured confounding) could be
affecting our results. Over-the-counter (OTC) medications
are not recorded in our source of information. Yet, it
should be noted that OTC long-term use of tNSAIDs or
cardioprotective aspirin is uncommon in the UK and
could have slightly underestimated our measures of asso-
ciation, in particular ibuprofen.
Conclusion
The overall experience with tNSAIDs in our study is gen-
erally congruent with a neutral effect on cardiovascular
disease although there is a suggestion of a small excess risk
with chronic exposure, especially for non-fatal MI. The
summary estimate for the tNSAID group is composed of
substantial variation in risk between the three studied
individual tNSAIDs suggesting a biologically plausible
heterogenity in cardiovascular risk [1,12]. Our study sug-
gests either no effect or a small reduction of cardiovascular
risk during sustained treatment with naproxen, a small
increased risk with diclofenac, and an undetectable risk
with ibuprofen. Larger observational studies and, if at all
possible, randomised clinical trials will be necessary to
address this hypothesis of mechanistic heterogenity
amongst tNSAIDs with respect to cardiovascular risk.
Abbreviations
cyclo-oxygenase-2 :COX-2
myocardial infarction: MI
Table 2: Duration of NSAID use among current users (use within a month) and risk of MI stratified by aspirin use and NSAID daily 
dose*
Cases (%) Controls (%) OR (95%CI)
Aspirin non users†
NSAID duration
Dura 0–30 days 100 (28.2) 481 (31.2) 1.03 (0.81–1.30)
Dura 31–365 days 149 (42.0) 680 (44.1) 1.04 (0.85–1.27)
Dura >365 days 106 (29.8) 381 (24.7) 1.29 (1.01–1.65)
Aspirin current users†
NSAID duration
Dura 0–30 days 46 (26.4) 91 (28.8) 0.94 (0.64–1.40)
Dura 31–365 days 77 (44.3) 126 (39.9) 1.08 (0.78–1.50)
Dura >365 days 51 (29.3) 99 (31.3) 0.90 (0.61–1.32)
NSAID low-medium dose‡
NSAID duration
Dura 0–30 days 92 (28.5) 350 (31.3) 1.04 (0.81–1.34)
Dura 31–365 days 136 (42.1) 484 (43.4) 1.05 (0.84–1.32)
Dura >365 days 95 (29.4) 282 (25.3) 1.30 (1.00–1.71)
NSAID high dose‡
NSAID duration
Dura 0–30 days 70 (27.2) 269 (30.8) 0.98 (0.73–1.31)
Dura 31–365 days 110 (42.8) 382 (43.8) 1.10 (0.86–1.41)
Dura >365 days 77 (30.0) 222 (25.4) 1.21 (0.90–1.64)
* Duration of use was computed adding the periods of "consecutive" prescriptions, defined as an interval of less than one month between the end 
of supply of one prescription and the date of prescription of the subsequent one.
† Estimates are adjusted for sex, age, calendar year, anemia, smoking status, alcohol use, diabetes, hypertension, hyperlipidemia, BMI, RA, OA, prior 
cardiovascular disease, use of steroids, anticoagulants and paracetamol.
‡ Estimates are adjusted for sex, age, calendar year, anemia, smoking status, alcohol use, diabetes, hypertension, hyperlipidemia, BMI, RA, OA, prior 
cardiovascular disease, use of steroids, anticoagulants, aspirin and paracetamol. Cut-off values for dose in mg were: aceclofenac 100, acemetacin 
120, apazone 600, diclofenac 75, etodolac 400, fenbufen 900, fenoprofen 1200, flurbiprofen 150, ibuprofen 1200, indomethacin 75, ketoprofen 100, 
mefenamic 1000, meloxicam 7.5, nabumetone 1000, naproxen 500, piroxicam 10, sulindac 200, tenoxicam 10, and tiaprofenic acid 450.Publish with BioMed Central    and   every 
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